Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

CCR5

  • Gero HütterEmail author
Reference work entry
First Online:
DOI: https://doi.org/10.1007/978-3-319-67199-4_101567
How to cite

Synonyms

 CCCKR5;  CC-CKR-5;  CCR-5;  CD195;  CKR5;  CKR-5;  CMKBR5;  IDDM22

Historical Background

The CC chemokine receptor 5 (CCR5) belongs to the G protein-coupled receptor (GPCR) family. Chemokines and their receptors were initially discovered in the context of cell trafficking and effector functions in cells of the immune system. Before CCR5 was described as receptor, one of its inhibitory ligands (RANTES, regulated on activation, normal T cell expressed and secreted) was found in the late 1980s as a molecule derived from T-cells (Schall et al. 1988). However, this detection of the ligand did not facilitate the detection of the corresponding receptor. This first description of CCR5 was part of the search for the entry mechanism of the human immunodeficiency virus type 1 (HIV-1) in the mid-1990s. At this time, it was well described that the T-cell receptor CD4 is mandatory for transmission of HIV-1 but the virus requires an additional unknown coreceptor for invasion. CCR5 was found...

This is a preview of subscription content, log in to check access.

References

  1. Burke BP, Boyd MP, Impey H, Breton LR, Bartlett JS, Symonds GP, et al. CCR5 as a natural and modulated target for inhibition of HIV. Viruses. 2013;6:54–68.  https://doi.org/10.3390/v6010054.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Clegg AO, Ashton LJ, Biti RA, Badhwar P, Williamson P, Kaldor JM, et al. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group. Aids. 2000;14:103–8.PubMedCrossRefGoogle Scholar
  3. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811–5.PubMedCrossRefGoogle Scholar
  4. Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. J Neuroinflammation. 2015;12:233.  https://doi.org/10.1186/s12974-015-0447-9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Gornalusse GG, Mummidi S, Gaitan AA, Jimenez F, Ramsuran V, Picton A, et al. Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proc Natl Acad Sci U S A. 2015;112:E4762–71.  https://doi.org/10.1073/pnas.1423228112.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Hütter G, Neumann M, Nowak D, Klein S, Klüter H, Hofmann WK. The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation. J Inflamm (Lond). 2011;8:29.  https://doi.org/10.1186/1476-9255-8-29.CrossRefGoogle Scholar
  7. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA. 2006;296:815–26.  https://doi.org/10.1001/jama.296.7.815.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.PubMedCrossRefGoogle Scholar
  9. Marsden V, Donaghy H, Bertram KM, Harman AN, Nasr N, Keoshkerian E, et al. Herpes simplex virus type 2-infected dendritic cells produce TNF-alpha, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells. J Immunol. 2015;194:4438–45.  https://doi.org/10.4049/jimmunol.1401706.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16:1201–10.  https://doi.org/10.1016/j.cellsig.2004.04.007.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Palmer LA, Sale GE, Balogun JI, Li D, Jones D, Molldrem JJ, et al. Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:311–9.  https://doi.org/10.1016/j.bbmt.2009.12.002.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367:135–45.  https://doi.org/10.1056/NEJMoa1201248.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Rottman JB, Ganley KP, Williams K, Wu L, Mackay CR, Ringler DJ. Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol. 1997;151:1341–51.PubMedPubMedCentralGoogle Scholar
  14. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Clayberger C, Davis MM, et al. A human T cell-specific molecule is a member of a new gene family. J Immunol. 1988;141:1018–25.PubMedPubMedCentralGoogle Scholar
  15. Vilela MC, Lima GK, Rodrigues DH, Lacerda-Queiroz N, Pedroso VS, Miranda AS, et al. Absence of CCR5 increases neutrophil recruitment in severe herpetic encephalitis. BMC Neurosci. 2013;14:19.  https://doi.org/10.1186/1471-2202-14-19.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Cellex IncDresdenGermany
  2. 2.Technical UniversityDresdenGermany